TP53 and acute myeloid leukemia: AML patients with TP53m have significantly poorer prognosis and lower overall survival (6.5 vs. 33.6 months) compared to TP53 wild-type AML patients due to resistance to standard AML therapies [13]; worse outcomes have been reported for TP53m patients compared to TP53 wild-type patients following treatment with IC or low-intensity chemotherapy [9].